文献速递白血病造血干细胞移植与细胞治疗

单倍体移植对高危急性髓系白血病首次完全缓解的移植物抗白血病效应可能优于同胞全合移植:前瞻性多中心队列研究

Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study.
PubMed 文献 · Leukemia · 2019-12-12

单倍体组移植后微小残留病阳性累积发生率18%显著低于同胞全合组42%(p<0.001),3年无移植物抗宿主病及复发生存率63%显著高于43%(p=0.035),提示单倍体移植可能具有更强移植物抗白血病效应。

要点

  • 单倍体移植后微小残留病阳性累积发生率18%,显著低于同胞全合移植的42%(p<0.001)
  • 单倍体组3年无GVHD及复发生存率63%,显著高于同胞全合组的43%(p=0.035)
  • 单倍体移植可作为高危急性髓系白血病首次完全缓解后缓解后治疗的优选方案之一

核心结论

  • 在高危急性髓系白血病首次完全缓解患者中,单倍体移植可能比同胞全合移植具有更强的移植物抗白血病效应。
  • 单倍体移植作为缓解后治疗应被推荐为高危急性髓系白血病首次完全缓解患者的优选选择之一。

研究设计与样本

  • 按供者可得性(生物学随机化)分为单倍体移植组83例和同胞全合移植组106例。
  • 主要终点为移植后微小残留病阳性发生率,所有移植后微小残留病阳性患者均接受抢先干预。

主要发现

  • 单倍体组和同胞全合组移植后微小残留病阳性累积发生率分别为18%和42%(p<0.001)。
  • 单倍体组和同胞全合组3年复发累积发生率分别为14%和24%(p=0.101)。
  • 单倍体组和同胞全合组3年治疗相关死亡率分别为15%和10%(p=0.368)。
  • 单倍体组和同胞全合组3年总生存率分别为72%和68%(p=0.687),3年无病生存率分别为71%和66%(p=0.579),3年无移植物抗宿主病及复发生存率分别为63%和43%(p=0.035)。

关键数值与推荐

  • 移植后微小残留病阳性累积发生率:单倍体组18% vs 同胞全合组42%(p<0.001)。
  • 抢先供者淋巴细胞输注比例:单倍体组16%(13例) vs 同胞全合组37%(39例)(p=0.001)。
  • 3年无移植物抗宿主病及复发生存率:单倍体组63% vs 同胞全合组43%(p=0.035)。

临床怎么用

  • 对于首次完全缓解的高危急性髓系白血病患者,单倍体移植可作为缓解后治疗的优选方案之一。
  • 移植后应监测微小残留病,阳性患者需接受抢先干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to investigate graft-versus-leukemia (GVL) of haploidentical donor (HID) compared with HLA-matched sibling donor (MSD) for high-risk acute myeloid leukemia (H-AML) in first complete remission (CR1). One hundred and eighty-nine patients with H-AML in CR1 were enrolled in this multicentre prospective cohort study. Patients were assigned to groups transplanted with HID (n = 83) or MSD (n = 106) based on donor availability (biological randomization). The primary endpoint was the incidence of MRD positivity posttransplantation (post-MRD+). All post-MRD+ patients received preemptive interventions. The cumulative incidences of post-MRD+ were 18 and 42% in HID and MSD groups, respectively, (p < 0.001). Fifty-two patients received preemptive DLI, including 13 (16%) in HID and 39 cases (37%) in MSD groups (p = 0.001). Among HID and MSD groups, the 3-year cumulative incidence of relapse were 14 and 24% (p = 0.101); the 3-year cumulative incidence of treatment-related mortality were 15 and 10% (p = 0.368); the 3-year overall survival rates were 72 and 68% (p = 0.687); the 3-year disease-free-survival were 71 and 66% (p = 0.579); the 3-year graft-versus-host disease and relapse free survival were 63 and 43% (p = 0.035), respectively. HID might have a stronger GVL than MSD in H-AML patients. HID transplantation as postremission therapy should be recommended as one of the optimal choices for H-AML patients in CR1.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Yu S, Huang F, Wang Y, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2019. PMID: 31831845. doi:10.1038/s41375-019-0686-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。